Stock Analiz

Kiora Pharmaceuticals Inc. KPRX

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.23Market cap $5M
Open the interactive analysis →

Kiora Pharmaceuticals Inc. (KPRX) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$13M, a net margin of -1276.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -84%.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $669259 in 2016 to $16M in 2024, growth of about 48.7% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 4944% over three years (dilution for shareholders).

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.4
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-145.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)22.4%
ROIC (5-yr avg.)-83.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$0$16M$0—$0$12059$3M$2M$407518$669259
Net income-$13M-$11M$4M-$13M-$14M-$14M-$7M-$7M-$11M-$13M-$13M
Free cash flow-$8M-$10M$9M-$10M-$10M-$11M-$7M-$8M-$11M-$7M-$8M
EPS (diluted)$-2.80$-2.64$0.87$-24.25$-166.95$-514.08$-536.40$-802.80$-1645.20$-5022.00$-8154.01
Net margin-1276.3%—22.4%———-56901.6%-264.2%-654.2%-3243.5%-1993.8%
ROIC—-69.6%11.1%-159.9%-106.0%-94.9%-52.7%—-95.9%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $7.00, 469% above the current price; targets range from $7.00 to $7.00; the consensus rating is “Buy”; expected EPS is $-1.05 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Kiora Pharmaceuticals pay a dividend?

Not currently.

Is Kiora Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Kiora Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.